Andrew Brenner Selected Research

paclitaxel-Angiopep-2 conjugate

3/2013	Phase I study of GRN1005 in recurrent malignant glioma.
2/2012	Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew Brenner Research Topics

Disease

15	Neoplasms (Cancer) 01/2022 - 02/2012
8	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 01/2016
6	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2019
3	Brain Neoplasms (Brain Tumor) 01/2021 - 02/2012
3	Glioma (Gliomas) 01/2016 - 05/2012
2	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2014
2	Fatigue 04/2021 - 03/2013
2	Lymphoma (Lymphomas) 01/2020 - 10/2019
1	Alopecia (Baldness) 04/2021
1	Pneumonia (Pneumonitis) 04/2021
1	Peripheral Nervous System Diseases (PNS Diseases) 04/2021
1	Nausea 04/2021
1	Microsatellite Instability 01/2020
1	Carcinogenesis 01/2019
1	Genomic Instability 01/2019
1	Medulloblastoma 10/2018
1	Meningioma (Meningiomas) 09/2018
1	Hypoxia (Hypoxemia) 01/2018
1	Infections 06/2014
1	Neutropenia 03/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2012
1	Ovarian Neoplasms (Ovarian Cancer) 02/2012

Drug/Important Bio-Agent (IBA)

6	Estrogen ReceptorsIBA 01/2022 - 05/2012
4	Pharmaceutical PreparationsIBA 04/2021 - 02/2012
3	Estrogens (Estrogen)FDA Link 01/2022 - 05/2012
3	Bevacizumab (Avastin)FDA Link 01/2021 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2019
2	taxaneIBA 04/2021 - 02/2012
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 03/2013 - 02/2012
2	paclitaxel-Angiopep-2 conjugateIBA 03/2013 - 02/2012
2	Peptides (Polypeptides)IBA 03/2013 - 02/2012
2	Low Density Lipoprotein Receptor-Related Protein-1 (LDL-Receptor Related Protein)IBA 03/2013 - 02/2012
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	carbazoleIBA 01/2022
1	olaparibIBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Imipramine (Janimine)FDA LinkGeneric 01/2022
1	TVB-2640IBA 04/2021
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 04/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Immunotoxins (Immunotoxin)IBA 01/2021
1	Capecitabine (Xeloda)FDA Link 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2021
1	Trastuzumab (Herceptin)FDA Link 01/2021
1	tucatinibIBA 01/2021
1	Nonesterified Fatty Acids (NEFA)IBA 12/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020
1	N 30IBA 01/2020
1	Temozolomide (Temodar)FDA LinkGeneric 10/2019
1	Estrogen Receptor betaIBA 01/2019
1	Caspase 3 (Caspase-3)IBA 01/2019
1	Phenobarbital (Luminal)FDA Link 01/2019
1	Vincristine (Oncovin)FDA LinkGeneric 10/2018
1	isophosphamide mustard (IPAM)IBA 01/2018
1	Alkylating AgentsIBA 01/2018
1	Protein Isoforms (Isoforms)IBA 01/2018
1	ProdrugsIBA 01/2018
1	TH 302IBA 01/2018
1	erteberelIBA 01/2016
1	AlbuminsIBA 10/2014
1	Immunoglobulin M (IgM)IBA 06/2014
1	Immunoglobulin G (IgG)IBA 06/2014
1	CarcinogensIBA 05/2012
1	liquiritigeninIBA 05/2012
1	Angiopep-2IBA 02/2012

Therapy/Procedure

12	Therapeutics 01/2022 - 02/2012
3	Drug Therapy (Chemotherapy) 01/2022 - 05/2012
1	Immunotherapy 01/2021
1	Radiotherapy 09/2018